Exelixis (EXEL) 10-K2021 FY Annual report

Filed: 18 Feb 22, 5:05pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Abstract, academia, accessibility, Aduhelm, advocating, Alzheimer, America, answer, attached, attorney, belief, bempegaldesleukin, Bio, Biopharma, biotherapeutic, biparatropic, BIRC, bound, BTK, buyout, Cayman, CBM, cervical, composed, controversy, criterion, crystalline, Curium, cytotoxic, Darmstadt, declaratory, Delta, diffuse, disadvantage, dismissed, dismissing, Division, enzyme, EP, epigenetic, Exhibit, exhibited, feature, Germany, Goodman, great, hedge, hedging, hematological, HTA, ID, incomplete, indemnification, inflationary, injunctive, intolerant, iodine, Jacqueline, KGaA, light, longstanding, lymphocytic, lymphoid, lymphoma, mAb, mainland, malate, mantle, markedly, membrane, microsatellite, Microsoft, mismatch, modestly, molecularly, multinational, murlentamab, NHL, NHT, noninferiority, North, Notch, older, Omicron, opposed, outpatient, outreach, overcharged, panel, paradigm, Parent, partnership, payload, pediatric, percentile, plc, polymorphic, pre, precision, prejudice, prespecified, proliferation, quavonlimab, radioactive, rank, redirect, regular, reinforce, reintroduction, Relatedly, remitted, repair, rich, RNA, sabizabulin, salt, sarcoma, satellite, seal, shareholder, spurred, stay, STORM, subset, Telix, Teva, TF, thwart, transformation, TSR, undisclosed, uptake, USA, venture, verified, Veru, Vicki, virulent, voluntary, week, Wright, WuXi, Yen

Removed: absence, advent, AEs, alia, ALK, alteration, APC, assure, attack, avoiding, aware, Bank, binimetinib, bring, card, catenin, cease, cobrim, collateralized, convertible, coupled, critically, dabrafenib, DCR, Deerfield, degradation, disciplined, dosing, drawn, EGFR, encorafenib, enthusiasm, epithelial, finerenone, fluoropyrimidine, force, founded, fueled, gene, genetic, harboring, histology, historic, immunotherapy, incidence, intention, interested, interrupted, investigating, irinotecan, lacking, levantinib, loan, McKesson, move, mutation, notified, overcome, oxaliplatin, pazopanib, prepared, ratio, read, Reauthorization, release, repayment, rest, retrospective, reverted, scaled, score, Silicon, Simplifying, stabilization, step, subordinated, trametinib, tripled, Trump, unaudited, Valley, viewed, waived

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EXEL transcripts

EXEL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333- 241667, 333-226493, 333-223225, 333-218236, 333-214766, 333-212866, 333-209824, 333- 203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333- 147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated February 18, 2022, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2021.

/s/ Ernst & Young LLP

Redwood City, California

February 18, 2022